Technetium (99mTc) votumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | tumor antigen CTAA16.88 |
| Clinical data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) | |
Technetium (99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.[1] It was developed for the detection of colorectal tumors, but has never been marketed.[2]
The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.[3]
References[]
- ^ WHO Drug Information
- ^ EMA: Public Statement on HumaSPECT Archived 2007-06-10 at the Wayback Machine
- ^ EMA: Summary of Product Characteristics for HumaSPECT
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by . |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by . |
Categories:
- Radiopharmaceuticals
- Experimental cancer drugs
- Technetium-99m
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs